Qiagen NV, the European molecular testing firm, is exploring strategic options, including a potential sale, as fresh takeover interest has emerged. The company is collaborating with advisers, and its supervisory board is fielding preliminary interest from various potential suitors. Discussions have occurred with several potential buyers in recent weeks, including some U.S. strategics.
Several sources indicate that the planned departure of Qiagen's Chief Executive Officer, Thierry Bernard, as soon as a successor is found, removes a significant perceived obstacle to a potential deal. Bernard's upcoming exit was announced in November. This development has fueled renewed interest in the Netherlands-based company, which has attracted takeover inquiries in the past that ultimately did not lead to a sale.
Despite the recent activity, deliberations are still in their early stages, and there is no guarantee that the current discussions will culminate in a sale. Following the news, U.S.-listed shares of Qiagen saw a notable increase, rising more than 16% in afternoon trade. The company, however, declined to comment on the report.
